Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Stocks

Showing results (341-350 of 365) with videos related to

Pageof 37
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonistsLilian Alcaraz, Andrew Bailey, Elaine Cadogan, et al.
Science (New York, N.Y.)|June 26, 2025
Rapid polygenic adaptation in a wild population of ash trees under a novel fungal epidemicCarey L Metheringham, William J Plumb, William R M Flynn, et al.
Journal of Medicinal Chemistry|October 17, 2022
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary AngioedemaRebecca L Davie, Hannah J Edwards, D Michael Evans, et al.
Journal of Medicinal Chemistry|October 30, 2025
Correction to "Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema"Rebecca L Davie, Hannah J Edwards, D Michael Evans, et al.
Journal of Leukocyte Biology|May 23, 2020
Frontline Science: LPS-inducible SLC30A1 drives human macrophage-mediated zinc toxicity against intracellular Escherichia coliClaudia J Stocks, Jessica B von Pein, James E B Curson, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2019
Uropathogenic <i>Escherichia coli</i> employs both evasion and resistance to subvert innate immune-mediated zinc toxicity for disseminationClaudia J Stocks, Minh-Duy Phan, Maud E S Achard, et al.
ACS Medicinal Chemistry Letters|September 27, 2017
Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor AntagonistsNicholas Kindon, Glen Andrews, Andrew Baxter, et al.
Clinical Immunology (Orlando, Fla.)|May 5, 1999
A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthmaJ L Kishiyama, D Valacer, C Cunningham-Rundles, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of ActionMichael J Stocks, Lilian Alcaraz, Andrew Bailey, et al.
Clinical & Translational Immunology|November 1, 2021
Endothelial cells are not productively infected by SARS-CoV-2Lilian Schimmel, Keng Yih Chew, Claudia J Stocks, et al.
Pageof 37

Showing results (341-350 of 365) with videos related to

Sort By:
Pageof 37
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonistsLilian Alcaraz, Andrew Bailey, Elaine Cadogan, et al.
Science (New York, N.Y.)|June 26, 2025
Rapid polygenic adaptation in a wild population of ash trees under a novel fungal epidemicCarey L Metheringham, William J Plumb, William R M Flynn, et al.
Journal of Medicinal Chemistry|October 17, 2022
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary AngioedemaRebecca L Davie, Hannah J Edwards, D Michael Evans, et al.
Journal of Medicinal Chemistry|October 30, 2025
Correction to "Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema"Rebecca L Davie, Hannah J Edwards, D Michael Evans, et al.
Journal of Leukocyte Biology|May 23, 2020
Frontline Science: LPS-inducible SLC30A1 drives human macrophage-mediated zinc toxicity against intracellular Escherichia coliClaudia J Stocks, Jessica B von Pein, James E B Curson, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2019
Uropathogenic <i>Escherichia coli</i> employs both evasion and resistance to subvert innate immune-mediated zinc toxicity for disseminationClaudia J Stocks, Minh-Duy Phan, Maud E S Achard, et al.
ACS Medicinal Chemistry Letters|September 27, 2017
Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor AntagonistsNicholas Kindon, Glen Andrews, Andrew Baxter, et al.
Clinical Immunology (Orlando, Fla.)|May 5, 1999
A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthmaJ L Kishiyama, D Valacer, C Cunningham-Rundles, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of ActionMichael J Stocks, Lilian Alcaraz, Andrew Bailey, et al.
Clinical & Translational Immunology|November 1, 2021
Endothelial cells are not productively infected by SARS-CoV-2Lilian Schimmel, Keng Yih Chew, Claudia J Stocks, et al.
Pageof 37